Stocks and Investing
Stocks and Investing
Thu, March 30, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Wed, March 29, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Gregory Fraser Maintained (AMRX) at Strong Buy with Decreased Target to $4 on, Mar 29th, 2023
Gregory Fraser of Truist Securities, Maintained "Amneal Pharmaceuticals, Inc." (AMRX) at Strong Buy with Decreased Target from $5 to $4 on, Mar 29th, 2023.
Gregory has made no other calls on AMRX in the last 4 months.
There are 3 other peers that have a rating on AMRX. Out of the 3 peers that are also analyzing AMRX, 1 agrees with Gregory's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Gary Nachman of "BMO Capital" Maintained at Hold with Decreased Target to $4 on, Friday, March 3rd, 2023
These are the ratings of the 2 analyists that currently disagree with Gregory
- Balaji Prasad of "Barclays" Maintained at Buy with Decreased Target to $4 on, Friday, March 10th, 2023
- Nathan Rich of "Goldman Sachs" Maintained at Strong Buy with Decreased Target to $3 on, Friday, March 3rd, 2023
Contributing Sources